モデルマウスの世界市場：近交系マウス、ノックアウト・マウス、ハイブリッド・マウス、非近交系マウス、自然発生突然変異マウス...市場調査レポートについてご紹介

1 Introduction (Page No. – 21)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 25)
2.1 Research Methodology Steps
2.2 Secondary and Primary Research Methodology
2.2.1 Secondary Research
2.2.1.1 Key Data From Secondary Sources
2.2.2 Primary Research
2.2.2.1 Key Industry Insights
2.2.2.2 Key Data From Primary Sources
2.2.2.3 Key Insights From Primary Sources
2.3 Market Size Estimation Methodology
2.4 Market Forecast Methodology
2.5 Market Data Validation and Triangulation
2.6 Assumptions

3 Executive Summary (Page No. – 34)
3.1 Introduction
3.2 Current Scenario
3.3 Future Outlook
3.4 Conclusion

4 Premium Insights (Page No. – 39)
4.1 Global Mice Model Market
4.2 Geographic Analysis: Mice Care Products Market, By Type
4.3 Market, By Technology (2015 vs 2020)

5 Market Overview (Page No. – 43)
5.1 Introduction
5.2 Market Segmentation
5.3 Market Dynamics
5.3.1 Drivers
5.3.1.1 Ongoing Innovations in Mice Model
5.3.1.1.1 Mice Model for Immune Diseases
5.3.1.1.2 Mice Model for Cancer
5.3.1.1.3 Mice Model for Rare Diseases
5.3.1.2 Personalized Medicine to Fuel the Demand for Personalized Humanized Mice Model
5.3.1.3 Continuous Support in the Form of Grants and Investments
5.3.1.4 Increase in R&D Activities of Pharmaceutical Industries
5.3.1.5 Increasing Focus of Associations on the Development of Embryonic Stem (ES) Cells as Well as Knockout and Mutant Mice
5.3.1.5.1 International Mouse Phenotyping Consortium (IMPC)
5.3.1.5.2 International Knockout Mouse Consortium (IKMC)
5.3.2 Restraints
5.3.2.1 Increased Usage of Rat Models
5.3.2.2 Advances in Zebrafish Model Development
5.3.2.3 Increased Benefits From Cryopreservation
5.3.2.4 Regulations and Laws for Ethical Use of Animals in Research
5.3.2.4.1 The Animal Welfare Act (Awa)
5.3.2.4.2 Public Health Service Policy (PHS)On Humane Care and Use of Laboratory Animals
5.3.2.5 Alternative Methods to Animal Testing
5.3.3 Opportunities
5.3.3.1 Rising Demand of Humanized Mice Model
5.3.3.2 Increase in Monoclonal Antibody Production
5.3.4 Challenge
5.3.4.1 Need for Improved Mice Model

6 Mice Model Market, By Type (Page No. – 55)
6.1 Introduction
6.2 Inbred Mice
6.3 Outbred Mice
6.4 Genetically Engineered (Knockout & Knockin) Mice
6.5 Hybrid/Congenic Mice
6.6 Conditioned/Surgically Modified Mice
6.7 Spontaneous Mutant Mice

7 Mice Model Market, By Technology (Page No. – 65)
7.1 Introduction
7.2 Microinjection
7.3 Embryonic Stem Cell Injection
7.4 Nuclear Transferase
7.5 Other Technologies
7.5.1 Genetically Modified Sperm-Mediated Gene Transfer
7.5.2 Virus/Vector-Mediated Gene Transfer
7.5.3 Liposome-Mediated Dna and Electroporation of Dna
7.5.4 Biolistics
7.5.5 Crispr/Cas9, Talens, and Zfns

8 Mice Model Market, By Service (Page No. – 74)
8.1 Introduction
8.2 Breeding Services
8.3 Cryopreservation Services
8.4 Quarantine Services
8.5 Rederivation Services
8.6 Model In-Licensing Services
8.7 Genetic Testing Services
8.8 Other Services

9 Mice Model Market, By Disease (Page No. – 85)
9.1 Introduction
9.2 Oncology Mice Model
9.2.1 Continuous Grants/Funds to Support Cancer Research Studies
9.2.2 Agreements/Collaborations to Strengthen Cancer Research
9.2.3 Introduction of New Mice Model for Specific Cancers
9.2.4 Expansions to Support Cancer Research Facilities
9.3 Mice Model for Immunology and Inflammation Studies
9.4 Mice Model for Diabetes Studies
9.5 Mice Model for Cardiovascular Studies
9.6 Mice Model for Central Nervous System (CNS) Studies
9.7 Mice Model for Metabolism and Regulation Studies
9.8 Mice Model for Other Disease Studies

10 Mice Care Products Market, By Type (Page No. – 99)
10.1 Introduction
10.2 Cages
10.3 Feed
10.4 Bedding
10.5 Others

11 Mice Model Market, By Region (Page No. – 106)
11.1 Introduction
11.2 North America
11.2.1 U.S.
11.2.1.1 Revised Funding Plans By the Nih to Enhance Reproducibility of Results
11.2.1.2 Growing Biomedical Research in the U.S.
11.2.1.3 Monoclonal Antibody Production to Augment the Use of Mice Models
11.2.1.4 Continued and Responsible Use of Animals Ensured By Animal Care Organizations
11.2.1.5 Development of Biosimilars Boosting the Demand for Preclinical Services
11.2.1.6 Preclinical Activities By Cros and Pharmaceutical R&D
11.2.1.7 Partnerships Between Cros and Pharmaceutical Companies
11.2.2 Canada
11.2.2.1 Growing Stem Cell Research Activities in Canada
11.3 Europe
11.3.1 Germany
11.3.1.1 Launch of Pro-Test Deutschland
11.3.1.2 Flourishing Biotechnology Industry
11.3.2 U.K.
11.3.2.1 Investors Demand Strong Statistics for Animal Studies in the U.K.
11.3.2.2 Increase in Cell Therapy Preclinical Research
11.3.3 France
11.3.3.1 Funding for Rare Disease Projects in France
11.3.4 Rest of Europe (RoE)
11.3.4.1 Improving Biomedical Industry in Russia
11.3.4.2 Growth in Biosimilars Market Calls for Increased Preclinical Activities
11.3.4.3 Focus on Rare Disease Research Projects
11.3.4.4 Events Conducted By Animal Care Associations to Promote the Ethical Use of Mice
11.3.4.5 Increase in Tailored Mice Models for Diseases Like Cancer
11.4 Asia-Pacific
11.4.1 China
11.4.1.1 International Alliances for R&D Activities in China
11.4.1.2 Growing Foray of Pharmaceutical and Mice Model Suppliers in China
11.4.1.3 Increasing Investments From Government and Private Sectors in China’s Life Sciences Sector
11.4.1.4 Initiatives to Reduce Longer Approval Times
11.4.1.5 Mandatory Animal Testing for All Pharmaceutical Drugs and Cosmetics in China
11.4.1.6 Intellectual Property (IP) Breaches, A Challenge for the Chinese Market
11.4.2 Japan
11.4.2.1 Growth in Biomedical and Medical Research in Japan
11.4.2.2 Research Into Regenerative Medicines
11.4.3 India
11.4.3.1 Growing Presence of Global Players
11.4.3.2 Development of Bioclusters to Boost India’s Biotechnology Industry
11.4.3.3 R&D Activities By Indian Pharmaceutical Companies to Boost Preclinical Research
11.4.3.4 Likely Shift of Outsourcing Preclinical Activities From India Towards European Nations
11.4.3.5 Limited Infrastructural Facilities in India, A Major Hindrance to the Mice Model Market
11.4.3.6 Weak Intellectual Property Environment in India
11.4.4 Rest of Asia-Pacific (RoAPAC)
11.4.4.1 Influx of International Players
11.4.4.2 Ongoing Biomedical Research Activities in Australia to Strengthen the Market
11.4.4.3 Growth in Translational and Biomedical Research in Singapore
11.4.4.4 Increase in Animal Research in Malaysia
11.4.4.5 Rising Pharmaceutical and Biotechnology R&D Activities in Korea
11.5 Rest of World (RoW)
11.5.1.1 Pharmaceutical, Biotechnology, and Research Industries in Brazil to Bolster the Market
11.5.1.2 Favorable Business Environment for Pharmaceutical and Biotechnology Industries in Saudi Arabia and the Uae

12 Competitive Landscape (Page No. – 172)
12.1 Overview
12.2 Market: Market Share Analysis (2014)
12.2.1 Charles River Laboratories International, Inc.
12.2.2 the Jackson Laboratory
12.2.3 Taconic Biosciences, Inc.
12.2.4 Harlan Laboratories, Inc. (Envigo)
12.3 Competitive Situation and Trends
12.3.1 Collaborations, Agreements, Strategic Alliances Partnerships, and Joint Ventures
12.3.2 Grants & Funds
12.3.3 Licensing
12.3.4 New Product Launches
12.3.5 Expansions
12.3.6 Patents
12.3.7 Acquisitions
12.3.8 Others

13 Company Profiles (Page No. – 190)
13.1 Introduction
13.2 Charles River Laboratories International, Inc.
13.2.1 Business Overview
13.2.2 Products and Services Offered
13.2.3 Recent Developments
13.2.4 MnM View
13.3 The Jackson Laboratory
13.3.1 Business Overview
13.3.2 Products and Services Offered
13.3.3 Recent Developments
13.3.4 MnM View
13.4 Taconic Biosciences, Inc.
13.4.1 Business Overview
13.4.2 Products and Services Offered
13.4.3 Recent Developments
13.4.4 MnM View
13.5 Envigo
13.5.1 Business Overview
13.5.2 Products and Services Offered
13.5.3 Recent Developments
13.5.4 MnM View
13.6 Covance, Inc.
13.6.1 Business Overview
13.6.2 Products and Services Offered
13.6.3 Recent Developments
13.7 Janvier Labs
13.7.1 Business Overview
13.7.2 Products and Services Offered
13.7.3 Recent Developments
13.8 Harbour Antibodies Bv
13.8.1 Business Overview
13.8.2 Products Offered
13.8.3 Recent Developments
13.9 Transgenic, Inc.
13.9.1 Business Overview
13.9.2 Products and Services Offered
13.9.3 Recent Developments
13.10 Genoway SA
13.10.1 Business Overview
13.10.2 Products and Services Offered
13.10.3 Recent Developments
13.11 Sage Labs, Inc. (A Subsidiary of Horizon Discovery Group PLC)
13.11.1 Business Overview
13.11.2 Products and Services Offered
13.11.3 Recent Developments
13.12 Ingenious Targeting Laboratory
13.12.1 Business Overview
13.12.2 Products and Services Offered
13.12.3 Recent Developments

14 Appendix (Page No. – 231)
14.1 Discussion Guide
14.2 Company Developments (2012-2015)
14.2.1 Charles River Laboratories International, Inc.
14.2.2 The Jackson Laboratory (JAX)
14.2.3 Taconic Biosciences Inc.
14.2.4 Envigo
14.2.5 Covance, Inc.
14.2.6 Transgenic, Inc.
14.2.7 Genoway SA
14.2.8 Sage Labs, Inc.
14.3 Introducing RT: Real-Time Market Intelligence
14.4 Available Customizations
14.5 Related Reports